(Alliance News) - Genflow Biosciences PLC on Tuesday said it began trading on the OTCQB Venture Market in the US, in addition to its London Stock Exchange Main Market listing.

The London-based biotechnology company focused on longevity, with research & development facilities in Belgium, said this followed a successful application, and that this did not involve any capital raise.

Genflow Biosciences said the new US trading facility expanded its access to a broader pool of investors and allowed US investors to trade during US trading hours and in US dollars.

"This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange," said Chief Executive Officer Eric Leire.

Chair Tamara Joseph added: "Genflow is developing gene therapies that could address an important source of many global illnesses: aging.

"As the company moves into phase 1/2 clinical trials to treat potentially the orphan condition Werner syndrome, which causes premature aging, and [non-alcohol related steatohepatitis], a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors."

Shares in Genflow Biosciences were up 13% to 3.27 pence each in London on Tuesday morning. In New York, it will begin trading when markets open.

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.